investordatabase.org

Debiopharm Innovation Fund

debiopharm.com Direct investor

Debiopharm Innovation Fund is the strategic corporate investment fund of the Swiss biopharmaceutical company Debiopharm. It invests in digital health and data-driven start-ups that aim to transform pharmaceutical R&D and cancer care.

Debiopharm Innovation Fund is a corporate venture arm headquartered in Switzerland. It invests directly in companies, from pre-seed to Series A, in oncology, digital health, pharma R&D and clinical trial tech. Its stated cheque size is $3M – 5M. 150 $m under management and 21 portfolio companies, as it reports.

“We invest in start-ups powering pharma R&D transformation and cancer care innovation”

— Debiopharm Innovation Fund, own website
Layer
Direct investor
Type
Corporate venture
Stage
Pre-seed – Series A
Headquarters
Switzerland
Sectors
oncology, digital health, pharma R&D, clinical trial tech, digital medicine, AI/ML, real-world data, digital biomarkers
Cheque size
$3M – 5M
Assets under management
150 $m
Portfolio
21 companies

Team, as Debiopharm Innovation Fund publishes it

  • Marc Cikes Managing Director, Debiopharm Innovation Fund S.A.
  • Tom Gibbs Senior Investment Director, Debiopharm Innovation Fund S.A.
  • Nicolas Stalder Senior Investment Associate, Debiopharm Innovation Fund S.A.
  • Vincent Lepreux Investment Director, Debiopharm Innovation Fund S.A.
  • Cedric Odje Senior Investment Associate, Debiopharm Innovation Fund S.A.

Names and roles exactly as listed on debiopharm.com. Nothing else about these people is recorded.

Where this comes from

Every fact above was read from a page Debiopharm Innovation Fund publishes itself. Nothing is taken from third-party databases. Investment activity (deals, co-investors) is not yet recorded.

Is this record wrong or stale?
— it reaches us directly, no email address to look up.

Record 21886 · added 2026-11-16 · link last verified 2026-11-16 · confidence high

Similar investors

Listed under